Kali-Extracts Analyst Research Report From Goldman Small Cap Research Expected Next Week
December 28 2018 - 9:42AM
InvestorsHub NewsWire
Kali-Extracts Analyst Research
Report From Goldman Small Cap Research Expected Next Week
DALLAS, TX --
December 28, 2018 -- InvestorsHub NewsWire -- Kali, Inc.
(dba/Kali-Extracts, Inc.) (USOTC: KALY)
(“KALY”) today announced an Analyst Research Report covering the
company’s new business direction after acquiring a patented
cannabis extraction operation is expected to be published next
week. On November
15th, the company announced the acquisition of NCM
Biotech in a transaction that changed the business direction of the
company. After updating all required filings to bring
the company into compliance with its required OTCMarkets
reports, KALY management
subsequently announced engaging Goldman
Small Cap Research to initiative coverage of KALY’s new assets
and business direction. The purpose of this report is to
provide shareholders and interested investors more comprehensive
information on the company’s current operations in a single
document. The report will be filed on the OTCMarkets site. It
will include detailed asset and business descriptions, operational
financial analysis, comparisons to similar businesses, market
forecasts and KALY specific forecasts. The purpose of the
report is to enhance the OTCMarkets’ required disclosures by
providing information on the current operations in addition to the
OTCMarkets reports on historical
operations.
Recent KALY milestones published by the
company anticipated to be included in the analyst report
include:
Kali-Extracts, Inc. Releases Preclinical Research
Study Results on Therapy for Respiratory Disease Driving $11
Billion Treatment
Market
Kali-Extracts and Nouveau Announce 100 Acer Hemp
Farm and CBD Extraction Facility Made Possible By New Farm
Bill
KALY produces
pharmaceutical grade cannabis extracts that have been involved in
multiple clinical trials in addition to utilizing its patented
cannabis extraction process in the production of CBD infused
nutrition and wellness products to include its own Hemp4mula and
CBD infused waters produced by Puration, Inc. (USOTC:
PURA) (“PURA”).
KALY is partners
with PURA and Nouveau Life Pharmaceuticals (dba Nouveau) (USOTC:
NOUV) (“NOUV”) in a joint venture named US Cannabis Health for
the purpose of together developing partnerships with pharmaceutical
companies to develop cannabis pharmaceuticals. US Cannabis
Health recently announced its first agreement with Generex
Biotechnology, Corp. (OTCQB:
GNBT).
Learn more about
the KALY at www.kali-extracts.com.
Disclaimer/Safe
Harbor:
This news
release contains forward-looking statements within the meaning of
the Securities Litigation Reform Act. The statements reflect the
Company's current views with respect to future events that involve
risks and uncertainties. Among others, these risks include the
expectation that any of the companies mentioned herein will achieve
significant sales, the failure to meet schedule or performance
requirements of the companies' contracts, the companies' liquidity
position, the companies' ability to obtain new contracts, the
emergence of competitors with greater financial resources and the
impact of competitive pricing. In the light of these uncertainties,
the forward-looking events referred to in this release might not
occur. These statements have not been evaluated by the Food and
Drug Administration. These products are not intended to diagnose,
treat, cure, or prevent any disease.
Kali, Inc.
Frederick Ferri
ir@kali-extracts.com
(214) 210-0459
Nouveau Life Pharmaceuti... (PK) (USOTC:NOUV)
Historical Stock Chart
From Apr 2024 to May 2024
Nouveau Life Pharmaceuti... (PK) (USOTC:NOUV)
Historical Stock Chart
From May 2023 to May 2024
